Jane Street
UNCY icon

Jane Street’s Unicycive Therapeutics UNCY Stock Holding History

Jane Street’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.4K Sell
11,173
-61,070
-85% -$450K ﹤0.01% 10914
2026
Q1 		$475K Buy
+72,243
New +$473K ﹤0.01% 8171
2024
Q4 		– Sell
-4,125
Closed -$16.8K – 10647
2024
Q3 		$16.8K Buy
+4,125
New +$16.6K ﹤0.01% 9312

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Octagon Capital Advisors
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Diametric Capital
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Jane Street's UNCY Position: Q2 2026 in Review

Jane Street reduced its Unicycive Therapeutics (UNCY) stake by 85% in Q2 2026, selling an estimated $450K and leaving 11,173 shares worth $52.4K. The position accounts for ﹤0.01% of the portfolio, ranked #10914.

Jane Street first reported a position in UNCY in Q3 2024 and has held it in 3 quarters since. The position peaked at $475K in Q1 2026. 79 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Jane Street held 11,173 shares of Unicycive Therapeutics worth $52.4K as of Q2 2026.
  • Jane Street sold 61,070 Unicycive Therapeutics shares in Q2 2026, an estimated $450K.
  • Unicycive Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10914 holding.
  • Jane Street first reported a position in Unicycive Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Jane Street's Unicycive Therapeutics position peaked at $475K in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.